Scott Andrew  Smith net worth and biography

Scott Smith Biography and Net Worth

President of BioAtla
Mr. Smith joins BioAtla with 30 years of biotechnology and pharmaceutical industry experience. In his ten years at Celgene from 2008-2018 his leadership role expanded from Vice President of Global Marketing for Inflammation & Immunology, to Global Head of that division, to President of the Inflammation & Immunology Franchise to his appointment in 2017 as Celgene's President and Chief Operating Officer. With a particular emphasis and interest in immunology, Mr. Smith drove the growth of Celgene's Inflammation and Immunology division from 13 to more than 1,300 people worldwide and oversaw the clinical development, global registration and commercial success of the blockbuster drug Otezla. Mr. Smith's prior experience at Pharmacia (acquired by Pfizer) and at Biovail included global responsibility for sales and marketing, creating and executing commercial and business development strategies and contributing to regulatory and clinical development strategies. Mr. Smith also serves on the board of directors of Titan Pharmaceuticals, Triumvira Immunologics and Springbank Pharmaceuticals. Mr. Smith received both his BSc degree in Chemistry and Biology and his HBSc degree in Pharmacology and Toxicology from the University of Western Ontario and his Masters of International Business Management from the American Graduate School of International Management (Thunderbird).

What is Scott Andrew Smith's net worth?

The estimated net worth of Scott Andrew Smith is at least $266.96 thousand as of August 12th, 2025. Mr. Smith owns 314,807 shares of BioAtla stock worth more than $266,956 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Smith may own. Learn More about Scott Andrew Smith's net worth.

How do I contact Scott Andrew Smith?

The corporate mailing address for Mr. Smith and other BioAtla executives is , , . BioAtla can also be reached via phone at 858-558-0708 and via email at [email protected]. Learn More on Scott Andrew Smith's contact information.

Has Scott Andrew Smith been buying or selling shares of BioAtla?

Scott Andrew Smith has not been actively trading shares of BioAtla within the last three months. Most recently, Scott Andrew Smith sold 628 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $23.03, for a transaction totalling $14,462.84. Learn More on Scott Andrew Smith's trading history.

Who are BioAtla's active insiders?

BioAtla's insider roster includes Guy Levy (Director), Jay Short (CEO), Eric Sievers (Insider), Scott Smith (President), Lawrence Steinman (Director), Christian Vasquez (Insider), and Richard Waldron (CFO). Learn More on BioAtla's active insiders.

Scott Andrew Smith Insider Trading History at BioAtla

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2021Sell628$23.03$14,462.84View SEC Filing Icon  
11/29/2021Sell399$23.89$9,532.11View SEC Filing Icon  
11/24/2021Sell466$24.87$11,589.42View SEC Filing Icon  
11/22/2021Sell430$26.23$11,278.90View SEC Filing Icon  
10/1/2021Sell2,994$30.18$90,358.92View SEC Filing Icon  
8/26/2021Sell33,244$40.16$1,335,079.04368,568View SEC Filing Icon  
See Full Table

Scott Andrew Smith Buying and Selling Activity at BioAtla

This chart shows Scott Andrew Smith's buying and selling at BioAtla by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioAtla Company Overview

BioAtla logo
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.85
Low: $0.82
High: $0.90

50 Day Range

MA: $0.79
Low: $0.61
High: $1.22

2 Week Range

Now: $0.85
Low: $0.24
High: $1.72

Volume

875,065 shs

Average Volume

2,104,218 shs

Market Capitalization

$49.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01